
<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <title>Document Content</title>
    <style>
        body { font-family: Arial, sans-serif; line-height: 1.6; max-width: 900px; margin: auto; padding: 20px; }
        table { border-collapse: collapse; width: 100%; margin-top: 20px; margin-bottom: 20px; }
        th, td { border: 1px solid #cccccc; text-align: left; padding: 8px; font-size: 12px; }
        tr:nth-child(even) { background-color: #f9f9f9; }
        th { background-color: #3366CC; color: white; font-weight: bold; }
        h2 { color: #4F81BD; border-bottom: 2px solid #4F81BD; padding-bottom: 5px;}
        p { margin-block-start: 0.5em; margin-block-end: 0.5em; }
    </style>
</head>
<body>
    <p style="font-size: small; color: grey;"><i>abmd-10k 20170331.htm</i></p>
<p style="font-size: small; color: grey;"><i>Page 61 of 83</i></p>
<p style="font-size: small; color: grey;"><i>ABIOMED_10k_061.pdf</i></p>
<p>ABIOMED, INC. AND SUBSIDIARIES Consolidated Statements of Cash Flows (in thousands)</p>

<table>
	<tr>
		<th rowspan="2"></th>
		<th colspan="3">Fiscal Years Ended March 31,</th>
	</tr>
	<tr>
		<th>2017</th>
		<th>2016</th>
		<th>2015</th>
	</tr>
	<tr>
		<td>Operating activities:</td>
		<td></td>
		<td></td>
		<td></td>
	</tr>
	<tr>
		<td>Net income</td>
		<td>$ 52,116</td>
		<td>$ 38,147</td>
		<td>$ 113,688</td>
	</tr>
	<tr>
		<td>Adjustments required to reconcile net income to net cash provided by operating activities:</td>
		<td></td>
		<td></td>
		<td></td>
	</tr>
	<tr>
		<td>Depreciation and amortization</td>
		<td>6,202</td>
		<td>3,277</td>
		<td>2,770</td>
	</tr>
	<tr>
		<td>Bad debt expense</td>
		<td>159</td>
		<td>42</td>
		<td>(5)</td>
	</tr>
	<tr>
		<td>Stock-based compensation</td>
		<td>32,866</td>
		<td>29,053</td>
		<td>16,520</td>
	</tr>
	<tr>
		<td>Write-down of inventory</td>
		<td>3,085</td>
		<td>2,094</td>
		<td>2,231</td>
	</tr>
	<tr>
		<td>Excess tax benefit from stock-based awards</td>
		<td>(12,038)</td>
		<td>(3,567)</td>
		<td>(606)</td>
	</tr>
	<tr>
		<td>Deferred tax provision (benefit)</td>
		<td>25,803</td>
		<td>22,296</td>
		<td>(87,094)</td>
	</tr>
	<tr>
		<td>Change in fair value of contingent consideration</td>
		<td>1,590</td>
		<td>1,053</td>
		<td>510</td>
	</tr>
	<tr>
		<td>Changes in assets and liabilities:</td>
		<td></td>
		<td></td>
		<td></td>
	</tr>
	<tr>
		<td>Accounts receivable</td>
		<td>(11,550)</td>
		<td>(10,930)</td>
		<td>(7,970)</td>
	</tr>
	<tr>
		<td>Inventories</td>
		<td>(12,284)</td>
		<td>(11,473)</td>
		<td>(6,967)</td>
	</tr>
	<tr>
		<td>Prepaid expenses and other assets</td>
		<td>(2,366)</td>
		<td>(2,290)</td>
		<td>(1,479)</td>
	</tr>
	<tr>
		<td>Accounts payable</td>
		<td>7,565</td>
		<td>(2,645)</td>
		<td>3,372</td>
	</tr>
	<tr>
		<td>Accrued expenses and other liabilities</td>
		<td>22,223</td>
		<td>10,020</td>
		<td>6,011</td>
	</tr>
	<tr>
		<td>Deferred revenue</td>
		<td>1,745</td>
		<td>1,718</td>
		<td>2,309</td>
	</tr>
	<tr>
		<td>Net cash provided by operating activities</td>
		<td>115,116</td>
		<td>76,795</td>
		<td>43,290</td>
	</tr>
	<tr>
		<td>Investing activities:</td>
		<td></td>
		<td></td>
		<td></td>
	</tr>
	<tr>
		<td>Purchases of marketable securities</td>
		<td>(278,501)</td>
		<td>(260,975)</td>
		<td>(97,658)</td>
	</tr>
	<tr>
		<td>Proceeds from the sale and maturity of marketable securities</td>
		<td>205,482</td>
		<td>219,639</td>
		<td>71,530</td>
	</tr>
	<tr>
		<td>Acquisition of ECP and AIS, net of cash assumed</td>
		<td>—</td>
		<td>—</td>
		<td>(15,697)</td>
	</tr>
	<tr>
		<td>Purchase of other investment</td>
		<td>(2,899)</td>
		<td>(750)</td>
		<td>(2,850)</td>
	</tr>
	<tr>
		<td>Purchases of property and equipment</td>
		<td>(50,415)</td>
		<td>(15,624)</td>
		<td>(5,188)</td>
	</tr>
	<tr>
		<td>Net cash used for investing activities</td>
		<td>(126,333)</td>
		<td>(57,710)</td>
		<td>(49,863)</td>
	</tr>
	<tr>
		<td>Financing activities:</td>
		<td></td>
		<td></td>
		<td></td>
	</tr>
	<tr>
		<td>Proceeds from the exercise of stock options</td>
		<td>10,660</td>
		<td>9,771</td>
		<td>10,927</td>
	</tr>
	<tr>
		<td>Excess tax benefit from stock-based awards</td>
		<td>12,038</td>
		<td>3,567</td>
		<td>606</td>
	</tr>
	<tr>
		<td>Taxes paid related to net share settlement upon vesting of stock awards</td>
		<td>(20,105)</td>
		<td>(7,313)</td>
		<td>(2,805)</td>
	</tr>
	<tr>
		<td>Proceeds from the issuance of stock under employee stock purchase plan</td>
		<td>1,720</td>
		<td>1,135</td>
		<td>795</td>
	</tr>
	<tr>
		<td>Principal payments on capital lease obligation</td>
		<td>(446)</td>
		<td>—</td>
		<td>—</td>
	</tr>
	<tr>
		<td>Net cash provided by financing activities</td>
		<td>3,867</td>
		<td>7,160</td>
		<td>9,523</td>
	</tr>
	<tr>
		<td>Effect of exchange rate changes on cash</td>
		<td>(1,841)</td>
		<td>(415)</td>
		<td>(1,465)</td>
	</tr>
	<tr>
		<td>Net increase in cash and cash equivalents</td>
		<td>(9,191)</td>
		<td>25,830</td>
		<td>1,485</td>
	</tr>
	<tr>
		<td>Cash and cash equivalents at beginning of year</td>
		<td>48,231</td>
		<td>22,401</td>
		<td>20,916</td>
	</tr>
	<tr>
		<td>Cash and cash equivalents at end of year</td>
		<td>$ 39,040</td>
		<td>$ 48,231</td>
		<td>$ 22,401</td>
	</tr>
	<tr>
		<td>Supplemental disclosure of cash flow information:</td>
		<td></td>
		<td></td>
		<td></td>
	</tr>
	<tr>
		<td>Cash paid for income taxes</td>
		<td>$ 1,405</td>
		<td>$ 848</td>
		<td>$ 1,215</td>
	</tr>
	<tr>
		<td>Cash paid for interest on capital lease obligation</td>
		<td>354</td>
		<td>—</td>
		<td>—</td>
	</tr>
	<tr>
		<td>Supplemental disclosure of non-cash investing and financing activities:</td>
		<td></td>
		<td></td>
		<td></td>
	</tr>
	<tr>
		<td>Property and equipment under capital lease obligation</td>
		<td>16,784</td>
		<td>—
</td>
		<td>—
</td>
	</tr>
	<tr>
		<td>Property and equipment in accounts payable and accrued expenses</td>
		<td>5,692</td>
		<td>1,797</td>
		<td>193</td>
	</tr>
</table>
<p>The accompanying notes are an integral part of the consolidated financial statements.</p>
<p style="font-size: small; color: grey;"><i>F-7</i></p>
<p style="font-size: small; color: grey;"><i>file://usmdcvdi003.us.kworld.kpmg.com/GDC_Ops/Operations/Gayathri%20Krishnan/RPA%20Phase%20II/Kiran/HealthCare/ ... 7/23/2018</i></p>

</body>
</html>
